8958
S. Caddick et al. / Tetrahedron 56 (2000) 8953±8958
2. Goldberg, I. H. Frontiers in Pharmacology and Therapeutics,
Cancer Chemotherapy, Blackwell: Oxford, 1992.
3. For isolation of Kedarcidin, C-1027 and Maduropeptin see:
Kawata, S.; Ashizawa, J.; Hirama, M. J. Am. Chem. Soc. 1997,
119, 12012; Yoshida, K.-I.; Minami, Y.; Azuma, R.; Saeki, M.;
Otani, T. Tetrahedron Lett. 1993, 34, 2637; Schroeder, D. R.;
Colson, K. L.; Klohr, S. E.; Zein, N.; Langley, D. R.; Lee, M. S.;
Matson, J. A.; Doyle, T. W. J. Am. Chem. Soc. 1994, 116, 9351;
Edo, K.; Mizugaki, M.; Koide, Y.; Seto, H.; Furihata, K.; Otake,
N.; Ishida, N. Tetrahedron Lett. 1985, 26, 331.
CDCl3) 1.25 (9H, s), 2.81 (1H, br s), 4.01 (1H, d J2.3 Hz),
4.53±4.56 (1H, m), 6.17 (1H, d J6.1 Hz), 7.29 (1H, dd
J6.1, 1.8 Hz); dC (75 Hz, CDCl3) 28.2, 75.1, 76.4, 80.7,
131.3, 161.5, 205.0; HRMS (EI) [M2CH3]1 found
155.0703. C8H11O3 requires 155.0708.
trans-4-Benzyloxy-5-hydroxy-2-cyclopenten-1-one (1b).12
The general method was employed for the preparation of
1b. The quantities of reagents used were as follows: triethyl-
amine (14.4 g, 142 mmol), 5b (5.8 g, 28.4 mmol), DMF
(70 mL). (4.55 g, 78%), mp 55±568C. nmax 3424, 3056;
2871, 1724, 1627, 896 cm21; dH (300 MHz, CDCl3)
2.85 (1H, br s), 4.28 (1H, d, J2.2 Hz), 4.55 (1H, s), 4.74
(1H, d, J11.7 Hz), 4.88 (1H, d, J11.7 Hz), 6.30 (1H, d,
J6.1 Hz), 7.32±7.42 (5H, m), 7.48 (1H, d, J6.1 Hz); dC
(75 MHz, CDCl3) 72.4, 80.4, 82.5, 128.0, 128.1, 128.5,
132.1, 137.2, 159.0, 204.2; HRMS (EI) [M]1 found
204.0790. C12H12O3 requires 204.0786.
4. Myers, A. G.; Liang, J.; Hammond, M.; Harrington, P. M.; Wu,
Y. S.; Kuo, E. Y. J. Am. Chem. Soc. 1998, 120, 2103.
5. Caddick, S.; Delisser, V. M. Tetrahedron Lett. 1997, 38, 2355.
6. Caddick, S.; Khan, S.; Smith, N. J.; Barr, D. M.; Delisser, V. M.
Tetrahedron Lett. 1997, 38, 5035.
7. Achmatowicz Jr., O.; Bukowski, P.; Szechner, B.;
Zwierzchowska, Z.; Zamoiski, A. Tetrahedron 1971, 27, 1973±
1996.
8. Weeks, P. D.; Kuhla, D. E.; Allingham, R. P.; Watson Jr., H. A.
Carbohydr. Res. 1977, 56, 195±199.
3-t-Butoxy-2-hydroxy-cyclopent-2-enone (6). To a stirred
solution of trans-4-t-butoxy-5-hydroxy-2-cyclopenten-1-
one (0.3071 g, 1.81 mmol, 1 equiv.) in anhydrous methanol
(5 mL), was added NEt3 (1.26 mL, 9.03 mmol, 5.0 equiv.)
via syringe and heated at 608C for 23 h. The reaction was
concentrated in vacuo to give a brown oil. Puri®cation of
this oil was achieved by ¯ash chromatography on silica gel
eluting with petrol:ethyl acetate (3:1 v:v) as the eluent yield-
ing the title compound as a pale yellow oil (113 mg, 37%).
nmax 3306, 2978, 1728, 1615 cm21; dH (300 MHz, CDCl3)
1.47 (9H, s), 2.31±2.34 (2H, m), 2.38±2.41 (2H, m), 6.38
(1H, br s); dC (75 MHz, CDCl3) 25.1, 28.1, 28.7, 81.2,
129.9, 160.0, 200.2; HRMS (EI) [M]1 found 170.0959,
C9H14O3 requires 170.0943.
9. Formation of the hydroxypyranone has been achieved using this
method: Shanmugam, Ponnusamy; Nair, Vijay Synth. Commun.
1996, 3007±3014.
10. Formation of the corresponding hydroxypyranone achieved
using this method; Laliberte, R., et al. J. Med. Chem. 1973, 16,
1084±1089.
11. Mucha, B.; Hoffmann, H. M. R. Tetrahedron Lett. 1989, 30,
4489±4492.
12. Kolb, H. C.; Hoffmann, H. M. R. Tetrahedron 1990, 46, 5127±
5144.
13. Caddick, S.; Khan, S. J. Chem. Soc., Chem. Commun. 1995,
1971±1972.
14. Prolonged heating (.24 h) leads to a dramatic reduction in the
yield of desired product and the formation of 3-t-butoxy-2-
hydroxy-cyclopent-2-enone.
Acknowledgements
15. Sammes, P. G.; Street, L. J. J. Chem. Soc., Perkin Trans. 1
1983, 1261±1265; Hendrickson, J. B.; Farina, J. S. J. Org. Chem.
1980, 45, 3359±3361; Wender, P. A.; Yoon Lee, H.; Wilhelm,
R. S.; Williams, P. D. J. Am. Chem. Soc. 1989, 111, 8954±8957.
16. Tanaka, H.; Kobayasi, Y.; Torii, S. J. Org. Chem. 1976, 41,
3482±3484.
We thank AstraZeneca and the Association for International
Cancer Research for their support of this work. We also
thank BBSRC, EPSRC, GlaxoWellcome, SmithKline
Beecham and Novartis for support of our programme. We
thank the University of Sussex for providing the funds to
establish the Centre for Biomolecular Design and Drug
Development. We are grateful to Drs Abdul-Sada, Avent
and Hitchcock (Sussex) for assistance and the EPSRC
Mass Spectrometry Service (Swansea) for mass spectra.
17. Kuo, Yueh-Hsiung; Shih, Kae-Shyang Heterocycles 1990, 31,
1941±1949; Constantinou-Kokotou, V.; Couladouros, E. A.;
Georgiadis, M. P.; Kokotos, G.; Georgiadis, T. M. Carbohydr.
Res. 1991, 222, 163±172; Hoffmann, H. M. R.; Krumwiede, D.;
Mucha, B.; Oehlerking, H. H.; Prahst, G. W. Tetrahedron 1993, 49,
8999±9018.
18. Constantinou-Kokotou, V.; Kokotos, G.; Georgiadis, M. P.
Liebigs Ann. Chem. 1991, 2, 151±154.
References
19. Grynkiewicz, G.; Barszazak, B.; Zamojski, A. Synthesis 1979,
364±365.
1. Lhermitte, H.; Grierson, D. S. Cont. Org. Synth. 1996, 3, 41;
ibid. 93; Nicolaou K. C.; Smith A. L. J. Med. Chem. 1996, 39,
2103; Murphy, J. A.; Grif®ths, J. Nat. Prod. Rep. 1993, 550 and
references therein.
20. Caddick, S.; Delisser, V. M.; Doyle, V. E.; Khan, S.; Avent, A.
G.; Vile, S. Tetrahedron 1999, 55, 2737±2754.